In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Prostate Cancer Prevention Endpoint May Have Been Key Problem As ODAC Votes Down BPH sNDAs

Executive Summary

The problems that GlaxoSmithKline and Merck had in trying to convince FDA's Oncologic Drugs Advisory Committee to add labeling on prostate cancer risk reduction to Avodart (dutasteride) and Proscar (finasteride) may have been avoided had the firms selected a stronger mortality endpoint for their trials.
Advertisement

Related Content

Teratogenic Drugs Pose Little Risk To Partners Of Male Patients, FDA Panel Says
Can Wealth Of Molecular Data Enable Promise Of Chemoprevention?
Can Wealth Of Molecular Data Enable Promise Of Chemoprevention?
"Risk Reduction" Indications Face A Higher Bar For Approval, May Require Specialized Prescribers
Tempers Flare At ODAC Meeting, And Pazdur Must Call "Order In The Court"
Tempers Flare At ODAC Meeting, And Pazdur Must Call "Order In The Court"
Nothing Benign About It: BPH Drugs' Bids For Prostate Cancer Risk Reduction Voted Down By Advisory Committee
Prostate Cancer Risk Reduction sNDAs Go Before ODAC, Pitting Statistical Versus Clinical Significance
Adult Vaccines Stand To Gain From Preventive Care Rule, Outreach Is Next
Adult Vaccines Stand To Gain From Preventive Care Rule, Outreach Is Next

Topics

Advertisement
UsernamePublicRestriction

Register

PS052940

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel